| 证券代码 | NDRM.O |
| 证券名称 | NeuroDerm Ltd |
| 证券类型 | 美股 |
| 上市场所 | 纳斯达克交易所 |
| 上市板块 | 主板 |
| 发行方式 | 公开发售 |
| 首发上市日 | 2014-11-14 |
| 首发价格(元) | 10 USD |
| 首发数量(股) | 4500000 |
| 首发募资额(元) | 45,000,000.00 USD |
| 首发主承销商 | Cowen and Company, LLC,Jefferies LLC |
| 货币单位 | USD |
| 公司名称 | NeuroDerm Ltd. |
| 注册地址 | 以色列 |
| 办公地址 | Ruhrberg Science Building, 3 Pekeris St., Rehovot, Israel |
| 成立日期 | 2003-03-18 |
| 董事会主席 | Robert Taub |
| 公司属地 | Israel 以色列 |
| 公司网址 | www.neuroderm.com |
| 电话 | +972 (8) 946-2729 |
| 传真 | +972 (8) 946-1729 |
| 公司简介 | NeuroDerm Ltd. is a clinical-stage pharmaceutical company developing next-generation treatments for central nervous system disorders, through proprietary formulations based on existing drugs that are intended to make a significant difference in patients' lives. NeuroDerm currently has four product candidates in development designed to treat moderate to severe Parkinson’s disease. The company designed its product candidates to overcome major deficiencies of current treatments and achieve enhanced clinical efficacy through continuous, controlled administration, primarily subcutaneously or transdermally. |